M14-465
Studienindikation: Rheumatoide Arthritis
Phase: Phase 3
Studienname:
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoide Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)
EudraCT-Nummer: 2015-003333-95